Mustang Bio Inc - ESG Rating & Company Profile powered by AI
This ESG rating includes 17 United Nations SDGs including: 'Quality Education', 'Responsible Production & Consumption' and 'Peace, Justice & Strong Institutions'. This ESG rating for Mustang Bio Inc represents the company's reporting of the UN Sustainable Development Goals. The report of Mustang Bio Inc leverages intelligence from across the internet as well as from public disclosures by Mustang Bio Inc.
Mustang Bio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.9; made up of an environmental score of 8.0, social score of 4.8 and governance score of 8.0.
6.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 290 | Qiagen NV | 7.0 | High |
| 290 | WuXi AppTec Co Ltd | 7.0 | High |
| 294 | Mustang Bio Inc | 6.9 | High |
| 294 | Cabaletta Bio Inc | 6.9 | High |
| 294 | Bicycle Therapeutics PLC | 6.9 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Mustang Bio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Mustang Bio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Mustang Bio Inc report the average age of the workforce?
Sign up for free to unlockDoes Mustang Bio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Mustang Bio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Mustang Bio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Mustang Bio Inc offer flexible work?
Sign up for free to unlockDoes Mustang Bio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Mustang Bio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Mustang Bio Inc conduct supply chain audits?
Sign up for free to unlockDoes Mustang Bio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Mustang Bio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Mustang Bio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Mustang Bio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Mustang Bio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Mustang Bio Inc disclose water use targets?
Sign up for free to unlockDoes Mustang Bio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Mustang Bio Inc have a product recall in the last two years?
Sign up for free to unlockDoes Mustang Bio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Mustang Bio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Mustang Bio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Mustang Bio Inc disclose parental leave metrics?
Sign up for free to unlockDoes Mustang Bio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Mustang Bio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Mustang Bio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Mustang Bio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Mustang Bio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Mustang Bio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Mustang Bio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Mustang Bio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Mustang Bio Inc disclose its waste policy?
Sign up for free to unlockDoes Mustang Bio Inc report according to TCFD requirements?
Sign up for free to unlockDoes Mustang Bio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Mustang Bio Inc disclose energy use targets?
Sign up for free to unlockDoes Mustang Bio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Mustang Bio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Mustang Bio Inc
These potential risks are based on the size, segment and geographies of the company.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.